Opinion
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...
Hosted on MSN28d
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
Hims launched in 2017, selling generic hair loss, sexual health, and skincare drugs online via telemedicine. It began selling weight loss copies in 2023.
Hims & Hers (HIMS) Investors Pulling Their Hair Out Over Pills Side-Effects
Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...
Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching End
Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...
Yahoo Finance19d
Hims & Hers' Weight-Loss Bet Hits a Wall--Is the Stock's $6 Billion Surge About to Unravel?
But with GLP-1 sales vanishing, Hims is left banking on generic weight-loss pills and its core business in hair-loss and ED treatments. While that business is solid, it doesn't justify the lofty ...
MarketWatch28d
Hims & Hers Health 4Q Revenue Surges on Boost From Weight-Loss Treatments
Hims & Hers Health said fourth-quarter revenue surged as demand for its weight-loss treatments took ... in its portfolio focus on sexual health, hair loss and mental health, among others.